Monoclonal Antibody Therapies against Anthrax

Abstract

Anthrax is a highly lethal infectious disease caused by the spore-forming bacterium Bacillus anthracis. It not only causes natural infection in humans but also poses a great threat as an emerging bioterror agent. The lethality of anthrax is primarily attributed to the two major virulence factors: toxins and capsule. An extensive effort has been made to generate therapeutically useful monoclonal antibodies to each of the virulence components: protective antigen (PA), lethal factor (LF) and edema factor (EF), and the capsule of B. anthracis. This review summarizes the current status of anti-anthrax mAb development and argues for the potential therapeutic advantage of a cocktail of mAbs that recognize different epitopes or different virulence factors.

Keywords

• Bacillus anthracis
• anti-PA mAbs
• anti-LF mAbs
• anti-EF mAbs
• anti-capsule mAbs
• post-exposure treatment of anthrax
• a cocktail of mAbs